Cheaper rituximab versions just as safe and effective for rare vasculitis?

NCT ID NCT05716334

Completed Disease control Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 201 Canadian patients with ANCA-associated vasculitis to see if cheaper biosimilar versions of rituximab work as well as the original drug. Researchers compared disease control, side effects, and how long it took to get insurance approval for treatment. The goal was to find out if biosimilars are a safe and effective alternative that could improve access to care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis microscopic polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS GRANULOMATOSIS WITH POLYANGIITIS MICROSCOPIC POLYANGIITIS

Contacts and locations

Locations

Centre Intégré Universitaire de Santé et de Services Sociaux du Nord-de-l'île-de-Montréal (CIUSSS NÎM) / Hôpital du Sacré-Coeur de Montréal

Montreal, Quebec, Canada
Lawson Research Institute (Western University)

London, Ontario, Canada
McGill University (Montreal General Hospital)

Montreal, Quebec, H3G 1A4, Canada
Ottawa Hospital Research Institute (Ottawa University)

Ottawa, Ontario, Canada
Sinai Health System (University of Toronto)

Toronto, Ontario, Canada
St Joseph's Healthcare Hamilton (McMaster University)

Hamilton, Ontario, Canada
University of Alberta

Edmonton, Alberta, Canada
University of British Columbia (Vancouver Coastal Health Authority)

Vancouver, British Columbia, Canada
University of Calgary

Calgary, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.